Amarin Pharms Company Profile
✉ Email this page to a colleague
What is the competitive landscape for AMARIN PHARMS, and when can generic versions of AMARIN PHARMS drugs launch?
AMARIN PHARMS has two approved drugs.
There are sixty-seven US patents protecting AMARIN PHARMS drugs.
There are two hundred and seventy-two patent family members on AMARIN PHARMS drugs in forty-three countries and eleven supplementary protection certificates in eight countries.
Summary for Amarin Pharms
| International Patents: | 272 |
| US Patents: | 67 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 2 |
Drugs and US Patents for Amarin Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amarin Pharms | VASCEPA | icosapent ethyl | CAPSULE;ORAL | 202057-001 | Jul 26, 2012 | AB | RX | Yes | Yes | 8,710,041 | See Plans and Pricing | See Plans and Pricing | |||
| Amarin Pharms | VASCEPA | icosapent ethyl | CAPSULE;ORAL | 202057-001 | Jul 26, 2012 | AB | RX | Yes | Yes | 8,709,475 | See Plans and Pricing | See Plans and Pricing | |||
| Amarin Pharms | VASCEPA | icosapent ethyl | CAPSULE;ORAL | 202057-001 | Jul 26, 2012 | AB | RX | Yes | Yes | 8,367,652 | See Plans and Pricing | See Plans and Pricing | |||
| Amarin Pharms | VASCEPA | icosapent ethyl | CAPSULE;ORAL | 202057-001 | Jul 26, 2012 | AB | RX | Yes | Yes | 8,642,077 | See Plans and Pricing | See Plans and Pricing | |||
| Amarin Pharms | VASCEPA | icosapent ethyl | CAPSULE;ORAL | 202057-001 | Jul 26, 2012 | AB | RX | Yes | Yes | 8,298,554 | See Plans and Pricing | Y | See Plans and Pricing | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Amarin Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Amarin Pharms | VASCEPA | icosapent ethyl | CAPSULE;ORAL | 202057-001 | Jul 26, 2012 | 8,188,146 | See Plans and Pricing |
| Amarin Pharms | VASCEPA | icosapent ethyl | CAPSULE;ORAL | 202057-002 | Feb 16, 2017 | 8,188,146 | See Plans and Pricing |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for AMARIN PHARMS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Capsules | 1 g | ➤ Subscribe | 2013-01-15 |
| ➤ Subscribe | Capsules | 500 mg | ➤ Subscribe | 2017-08-29 |
| ➤ Subscribe | Capsules | 1 g | ➤ Subscribe | 2016-07-26 |
International Patents for Amarin Pharms Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Croatia | P20201830 | See Plans and Pricing |
| Malaysia | 173616 | See Plans and Pricing |
| European Patent Office | 3278665 | See Plans and Pricing |
| Croatia | P20171766 | See Plans and Pricing |
| South Korea | 20170131722 | See Plans and Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Amarin Pharms Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2443246 | LUC00226 | Luxembourg | See Plans and Pricing | PRODUCT NAME: ICOSAPENT ETHYL; AUTHORISATION NUMBER AND DATE: EU/1/20/1524 20210329 |
| 2443246 | 39/2021 | Austria | See Plans and Pricing | PRODUCT NAME: ICOSAPENT-ETHYL (= EICOSAPENTAENSAEUREETHYLESTER,; REGISTRATION NO/DATE: EU/1/20/1524 20210329 |
| 2443246 | PA2021522 | Lithuania | See Plans and Pricing | PRODUCT NAME: IKOZAPENTO ETILAS; REGISTRATION NO/DATE: EU/1/20/1524 20210326 |
| 2443246 | 132021000000156 | Italy | See Plans and Pricing | PRODUCT NAME: ICOSAPENT ETILE(VAZKEPA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/20/1524, 20210329 |
| 0113964 | 97C0037 | Belgium | See Plans and Pricing | PRODUCT NAME: OESTROGENES EQUINS CONJUGUES; ACETATE DE MEDROXYPROGESTERONE; NAT. REGISTRATION NO/DATE: NL 19569 19950301; FIRST REGISTRATION: CH - 52647 01 010 19940826 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
